Oral Dosage Form Comprising Rosiglitazone
An oral dosage form, such as a bilayer tablet, comprising a first layer of a first composition and a second layer of a second composition, each composition comprising 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione or a pharmaceutically acceptable salt or solvate thereof, (‘the drug’) and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release drug at differing release rates on administration; a process for preparing such a dosage form; and the use of such a dosage form in medicine.
1 - 15 . (canceled)
16 . An oral dosage comprising a first layer of a first composition and a second layer of a second composition, each composition comprising a drug, wherein the drug is 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release the drug at differing release rates on administration.
17 . An oral dosage form according to claim 16 , wherein the release rate of the drug from the first composition is substantially greater than from the second composition.
18 . An oral dosage form according to claim 16 , wherein the first composition is an immediate release composition.
19 . An oral dosage form according to claim 16 , wherein the second composition is a modified release composition.
20 . An oral dosage form according to claim 16 , wherein the first composition is arranged so that in use it releases substantially all of the drug in the stomach.
21 . An oral dosage form according to claim 16 , wherein the second composition is arranged so that in use it releases substantially all of the drug in the small intestine.
22 . An oral dosage form according to claim 16 , which dosage form is arranged to release the drug such that the mean maximum plasma level concentration value of the drug is maintained substantially independent of food during use.
23 . An oral dosage form according to claim 16 , which dosage form is arranged to release the drug such that the mean area under the plasma concentration versus time curve over the dosing interval at steady state is maintained substantially independent of food during use.
24 . An oral dosage form according to claim 16 , which dosage form is arranged to release the drug so that both the mean maximum plasma level concentration value and the mean area under the plasma concentration versus time curve over the dosing interval at steady state observed on administration are maintained substantially independent of food during use.
25 . An oral dosage form according to claim 16 , wherein the first composition is formulated so that it provides immediate release of the drug on contact with aqueous media.
26 . An oral dosage form according to claim 16 , wherein the second composition is formulated so that it provides modified release of the drug on contact with aqueous media.
27 . An oral dosage form according to claim 16 , wherein the dosage form is a tablet form.
28 . An oral dosage form according to claim 27 in the form of a bilayer tablet comprising a first layer of an immediate release composition containing 3 mg (pfb) of the drug and a second layer of a modified release composition containing 5 mg (pfb) of the drug.
29 . A process for preparing an oral dosage form which dosage form comprises a first composition and a second composition, each composition comprising a drug, where the drug is 5-[4-[2-(N-methyl-N-(2 pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier therefor, wherein the first and second compositions are arranged to release the drug at differing release rates on administration such that the rate of release of the drug from the dosage form is substantially independent of pH;
which process comprises the steps of sequentially or simultaneously:
(i) formulating the drug into the first composition; and
(ii) formulating the drug into the second composition;
and the steps of sequentially or simultaneously:
(i) forming the first composition into a first layer; and
(ii) forming the second composition into a second layer; and
(iii) combining the layers into a multilayer dosage form,
whereby the first and second layers are formulated to release drug at differing release rates on administration such that the rate of release of the drug from the dosage form is substantially independent of pH.
30 . A process according to claim 29 , where, in step (iii), the first and second layers are combined into a bilayer dosage form.
31 . A method for the treatment or prophylaxis of a disorder selected from diabetes mellitus, conditions associated with diabetes mellitus, Alzheimer's Disease, mild cognitive impairment, psoriasis, asthma, atherosclerosis, metabolic syndrome, impaired glucose tolerance and impaired fasting glucose, in a human or non-human mammal, which method comprises administering the oral dosage form according to claim 16 , to a human or non-human mammal in need thereof.